Navigation Links
Vanda Pharmaceuticals Reports Second Quarter 2011 Results
Date:8/4/2011

r to the 10:00 AM start time and ask for the Vanda Pharmaceuticals conference call hosted by Dr. Polymeropoulos (participant passcode 16117516).  A replay of the call will be available beginning Thursday, August 4, 2011 at 1:00 PM ET and will be accessible until Thursday, August 11, 2011, at 5:00 PM ET.  The replay call-in number is 1-888-286-8010 for domestic callers and 1-617-801-6888 for international callers.  The access number is 57140859.

The conference call will be broadcast simultaneously on Vanda's website, http://www.vandapharma.com.  Investors should click on the Investor Relations tab and are advised to go to the website at least 15 minutes early to register, download, and install any necessary software or presentations.  The call will also be archived on Vanda's website for a period of 30 days, through September 3, 2011.

ABOUT VANDA PHARMACEUTICALS INC.:Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders.  For more on Vanda, please visit http://www.vandapharma.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTSVarious statements in this release are "forward-looking statements" under the securities laws. Words such as, but not limited to, "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," and "could," or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the company's forward-looking statements include, among others: the extent and effectiveness of the development, sales and ma
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
2. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
3. Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
4. Vanda Presents Phase III Iloperidone Efficacy Data
5. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
6. Vanda Pharmaceuticals Provides Update on Iloperidone
7. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
8. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
9. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
10. Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)
11. Vanda Pharmaceuticals Announces U.S. Patent Allowance for a Long-Acting Injectable Formulation of Fanapt(TM) (iloperidone) in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... , May 6, 2015  Membership in Medicare ... to a Healthcare Business Strategy report released by ... known as Medigap or Med Supp plans, covered ... 2014, a 5.2% increase from 2013. Between 2013 ... by 551,135 covered lives.  Though UnitedHealth was the ...
(Date:5/6/2015)... 2015  LumiThera Inc., a medical device company focused ... ocular disorders and disease, today announced Retired Congressman ... Board to assist in the company,s mission to treat ... was the U.S. Representative for Washington,s ... He is a member of the Democratic Party. His ...
(Date:5/6/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/jskhnb/energy_based ) has announced ... Global Strategic Business Report" report to their offering. ... Canada , Japan , ... and Rest of World. Annual estimates and forecasts are provided ... analysis is provided for these markets. The global ...
Breaking Medicine Technology:Continued Growth in Med Supp Market for 2014 according to Mark Farrah Associates 2Retired Congressman Norman Dicks Joins LumiThera's Advisory Team 2Energy based Ablation Devices - Global Strategic Business Report 2015: Increasing Incidence of Cancer Bodes Well For Energy Based Ablation Devices 2Energy based Ablation Devices - Global Strategic Business Report 2015: Increasing Incidence of Cancer Bodes Well For Energy Based Ablation Devices 3
... , ABBOTT PARK, Ill., Nov. 12 Nearly one in ... normal and nearly 34 million have low HDL "good" cholesterol ... HDL and trigs, Abbott has launched two Web sites: ... , "Unhealthy high triglyceride and low HDL levels are factors ...
... a leader in fluorescence in vivo imaging from ... new Cat B 750 FAST(TM) imaging agent for ... and therapeutic response in vivo . Cathepsin B ... target in a range of diseases, including atherosclerosis, oncology, and ...
Cached Medicine Technology:New Web Sites Educate About Triglycerides and HDL Cholesterol 2VisEn Launches New Cat B 750 Fast(TM) Fluorescence Molecular Imaging Agent at American Heart Association Meeting 2VisEn Launches New Cat B 750 Fast(TM) Fluorescence Molecular Imaging Agent at American Heart Association Meeting 3
(Date:5/7/2015)... Falls Church, Va. (PRWEB) May 07, 2015 ... operators use foodservice packaging, making it an integral ... Strategic Sourcing Guide provides direction to foodservice ... foodservice packaging. , Foodservice packaging refers to single-use ... restaurants and other establishments that offer prepared foods ...
(Date:5/7/2015)... 07, 2015 Five CHI Health ... Health Bergan Mercy, CHI Health Immanuel and CHI ... in Papillion, Neb.; and CHI Health Mercy in ... achieving high-quality standards of care by the Accreditation ... to best practices in cardiovascular care. The five ...
(Date:5/7/2015)... NY (PRWEB) May 07, 2015 Over a ... tooth. A broken tooth or a failing crown usually means ... the dentist result in more needle pokes to the ... while the new crown is fabricated. In addition, it takes ... more time than necessary. In the dental chair, Dr. Leonard ...
(Date:5/6/2015)... Church, VA (PRWEB) May 07, 2015 ... Impact of NSF/IPEC/ANSI 363-2014, **FDAnews Webinar**, May 27, ... http://www.fdanews.com/NewGMPStandards , Most drugs contain 70-90% ... aids, binding agents or other purposes that facilitate ... globalization of the pharma industry, combined with a ...
(Date:5/6/2015)... 2015 With recent headlines about the kidnapping ... by 6 men from Southern China, it is becoming apparent ... real concern for them. This is especially true for High ... attract unwanted attention through the property they own, the schools ... Fortunately for those individuals, families and companies that are at ...
Breaking Medicine News(10 mins):Health News:First-Ever Sourcing Guide Aids Purchasers of Foodservice Packaging 2Health News:Five CHI Health Facilities in Nebraska, Iowa Recognized for High-Quality Care by Accreditation for Cardiovascular Excellence 2Health News:Five CHI Health Facilities in Nebraska, Iowa Recognized for High-Quality Care by Accreditation for Cardiovascular Excellence 3Health News:Dr. Leonard Umanoff, DDS Uses New CEREC Crowns that Save Time for Dental Patients 2Health News:FDAnews Announces — New Standards for Excipient GMPs: Analyzing the Impact of NSF/IPEC/ANSI 363-2014 Webinar, May 27, 2015 2Health News:FDAnews Announces — New Standards for Excipient GMPs: Analyzing the Impact of NSF/IPEC/ANSI 363-2014 Webinar, May 27, 2015 3Health News:Pacific Prime China Now Offering Kidnapping & Ransom Insurance 2
... farmers have launched a new foundation to benefit farmworkers, ... for three programs related to child care, health care ... For its inaugural projects, the Farmworker Community Support ... Health Services and the Redlands Christian Migrant ...
... 2009 in World Journal of Gastroenterology addresses ... Kingdom of Saudi Arabia investigated, for the first time, ... is synthesized mainly in the liver, during the development ... deficiency is a risk factor and should be viewed ...
... the future of the cosmetic surgery industry. The ... the cosmetic surgery industry, conducted its annual Procedural Survey ... non-invasive laser treatments. , Over the past ... in both males (456%) and females (215%) electing to ...
... for Florida Providers JACKSONVILLE, Fla., March ... information network, announced today an expanded partnership with ... affordable health care to families and individuals. With ... to Molina Healthcare via the Availity secure web ...
... Robbins & Myers, Inc. (NYSE: RBN ) ... its regular cash dividend payment of $0.04 per share. ... to shareholders of record as of April 10, 2009.Robbins ... equipment and systems for critical applications in global energy, ...
... Now for Summer Relief! Woodward Laboratories adds a New ... NS Antifungal Treatment Line; Makes Diagnosing Nail Fungus Convenient ... 35 million Americans have nail fungus, but only 2.5 ... at Woodward Laboratories, a leading hand, foot and skin ...
Cached Medicine News:Health News:Growers Establish Foundation To Help Farmworkers With Child Care, Health Care and Education 2Health News:Growers Establish Foundation To Help Farmworkers With Child Care, Health Care and Education 3Health News:Growers Establish Foundation To Help Farmworkers With Child Care, Health Care and Education 4Health News:Long-term L-carnitine supplementation prevents development of liver cancer 2Health News:Record number of patients seek laser treatments to take lightyears off their faces 2Health News:Availity Expands Partnership with Molina Healthcare 2Health News:Toes With Nail Fungus Will Be Exposed During Upcoming Summer Sandal Months: Prepare Now 2Health News:Toes With Nail Fungus Will Be Exposed During Upcoming Summer Sandal Months: Prepare Now 3
The CryoSurgery console is the control center for CryoCath's surgical probe. It is a modular system made up of a console control unit and a tank dolly system. The system can be used as a unit or in s...
... minimally invasive cryocatheter to treat atrioventricular ... very high level of safety through ... minimal tissue disruption, and minimal risk ... allows physicians to surgically treat cardiac ...
... is a malleable, single-use cryosurgical probe developed ... The probe will ablate cardiac tissue while ... surgical procedure, such as coronary artery bypass ... and/or repair and as part of the ...
... has developed a minimally invasive cryocatheter ... It delivers a very high level ... pinpoint site precision, minimal tissue disruption, ... stenosis., ,Freezor is a flexible, single-use, ...
Medicine Products: